ARS Pharmaceuticals, Inc. (SPRY) Guidance & Earnings Results
On 2026-08-13 ARS Pharmaceuticals, Inc. reaffirmed guidance: "2H 2026 operating expense significantly reduced; path to cash flow breakeven by end of…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SPRYARS Pharmaceuticals, Inc.Follow SPRY — free
—
Price chart with a free account
- Market cap
- 400.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 13 Aug 26 | Reaffirmed | 2H 2026 operating expense significantly reduced; path to cash flow breakeven by end of 2027. |
| 10 Nov 25 | Reaffirmed | Gross-to-net retention ≥50% steady-state |
| 13 Aug 25 | Reaffirmed | Cash runway: financial position expected to support operating plans for at least next three years · full year |
ARS Pharmaceuticals, Inc. — questions
- What guidance did ARS Pharmaceuticals, Inc. give?
- On 2026-08-13: "2H 2026 operating expense significantly reduced; path to cash flow breakeven by end of 2027."
- When does ARS Pharmaceuticals, Inc. report earnings?
- ARS Pharmaceuticals, Inc.'s next earnings report is expected on 2026-11-17.
Every figure on this page comes from ARS Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.